---
title: "Taysha Gene Therapies (TSHA): Valuation Perspectives After Regaining TSHA-102 Rights and FDA Breakthrough Status"
description: "Taysha Gene Therapies (TSHA) regained full rights to its TSHA-102 gene therapy for Rett syndrome and received FDA Breakthrough Therapy status. The stock surged 62.8% in the past month and 155% year-to"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261760028.md"
published_at: "2025-10-19T08:55:35.000Z"
---

# Taysha Gene Therapies (TSHA): Valuation Perspectives After Regaining TSHA-102 Rights and FDA Breakthrough Status

> Taysha Gene Therapies (TSHA) regained full rights to its TSHA-102 gene therapy for Rett syndrome and received FDA Breakthrough Therapy status. The stock surged 62.8% in the past month and 155% year-to-date, with a 1-year total shareholder return of 129%. Analysts have a consensus price target of $6.55, with some predicting up to $8.0. The fair value is estimated at $9.50, indicating the stock is undervalued, but risks include regulatory approval challenges and ongoing unprofitability.

Taysha Gene Therapies (TSHA) regained full rights to its TSHA-102 gene therapy program for Rett syndrome after the expiration of an agreement with Astellas. This change restores their strategic flexibility at the same time the therapy received FDA Breakthrough Therapy status.

See our latest analysis for Taysha Gene Therapies.

Following a wave of positive clinical news and the return of full control over its lead program, Taysha Gene Therapies’ share price has surged, rising 62.8% in the past month and 155% year-to-date. Despite a small pullback this week, the stock’s 1-year total shareholder return stands at 129%, marking strong momentum that investors are watching closely as pivotal trial milestones approach.

If momentum in biotech breakthroughs has your attention, consider the next discovery opportunity: See the full list for free.

With the stock already up sharply and analysts raising their forecasts, the key question now is whether Taysha shares are still undervalued or if the market has already priced in the company’s anticipated growth.

## Most Popular Narrative: 50.3% Undervalued

Taysha Gene Therapies' most followed narrative assigns a fair value that is more than double its last close price of $4.72. This makes the stock appear deeply discounted relative to the projected outlook.

> *The analysts have a consensus price target of $6.55 for Taysha Gene Therapies based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $8.0 and the most bearish reporting a price target of just $5.0.*

Read the complete narrative.

Curious how they arrived at such a bold valuation for Taysha? The secret lies in ambitious growth forecasts and a profit outlook rarely seen in early-stage biotech. Want to see which key numbers truly drive this narrative and if they hold up to scrutiny? Push below the surface to uncover the full story behind this pricing.

**Result: Fair Value of $9.50 (UNDERVALUED)**

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are still key risks, including the challenge of gaining timely regulatory approval and the ongoing unprofitability, that could alter Taysha's trajectory.

Find out about the key risks to this Taysha Gene Therapies narrative.

## Build Your Own Taysha Gene Therapies Narrative

Not convinced by the consensus or want to reach your own conclusions? Dive into the data and craft your personal valuation in just a few minutes. Do it your way.

A great starting point for your Taysha Gene Therapies research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.

## Looking for More Investment Ideas?

Step ahead of the crowd by screening for opportunities most investors overlook. Tomorrow’s winners are waiting, so don’t let them slip by while others hesitate.

-   Capture steady income streams when you check out these 18 dividend stocks with yields > 3% offering yields above 3% and strong payout histories.
-   Spot untapped growth potential by checking these 24 AI penny stocks that are shaping the future with advanced artificial intelligence innovations.
-   Uncover hidden value by searching these 878 undervalued stocks based on cash flows that trade below their true worth based on cash flow analysis.

*This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.*

### Related Stocks

- [TSHA.US - Taysha Gene Therapies](https://longbridge.com/en/quote/TSHA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| EPS 創健科技計劃收購中國基因 16.23% 的股份 | EPS 創健科技將收購中國基因 16.23% 的股份 | [Link](https://longbridge.com/en/news/275820168.md) |
| Taysha Gene Therapies 在關鍵性 Rett 綜合症基因治療試驗中為首位患者進行給藥 | Taysha Gene Therapies Inc. 已經為其名為 REVEAL 的關鍵基因治療試驗給第一位患者進行了給藥，該試驗將招募 15 名年齡在 6 歲至 22 歲以下的女性患者。該試驗評估基於 AAV9 的基因治療 TSHA-10 | [Link](https://longbridge.com/en/news/271654132.md) |
| Genflow Biosciences 報告 SIRT6 基因療法在老年犬中的積極中期試驗結果 | Genflow Biosciences plc 報告了其 SIRT6 基因治療在老年比格犬中的 SLAB 臨牀試驗的積極中期結果。該研究涉及 24 只超過 10 歲的狗，顯示出在生存率、生活質量、肌肉保存和虛弱減少方面的改善，並且安全性良好 | [Link](https://longbridge.com/en/news/275712514.md) |
| Anixa Biosciences 的 CEO 稱 2026 年為 “關鍵之年”，因為乳腺癌疫苗和卵巢癌 CAR-T 療法的推進 | Anixa Biosciences 首席執行官 Amit Kumar 博士宣佈，2026 年將是公司一個關鍵的年份，因為它正在推進乳腺癌疫苗和卵巢癌 CAR-T 療法。關鍵里程碑包括完成疫苗的第一階段臨牀試驗，併為第二階段做準備。公司目前擁 | [Link](https://longbridge.com/en/news/275508535.md) |
| 奧本海默表示，福泰製藥的腎病療法可能會為其長期收入來源帶來多樣化 | Vertex 製藥的腎臟疾病療法可能會多樣化長期收入來源，Oppenheimer 表示 | [Link](https://longbridge.com/en/news/275926557.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
